{"entity":{"id":"nct07136181","kind":"trial","name":"Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma","aka":[],"tldr":"A phase 1/2 trial of NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers. in uveal melanoma, run by Novelwise Pharmaceutical Corporation, now recruiting.","summary":"Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma is a phase 1/2 interventional study registered as NCT07136181 by Novelwise Pharmaceutical Corporation, with 36 participants planned, started 2025-11-20 and due to reach its primary completion in 2028-03-28. Interventions recorded: NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers..","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07136181","url":"https://clinicaltrials.gov/study/NCT07136181"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["uveal-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07136181","phase":"1/2","setting":"A Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma","sponsor":"Novelwise Pharmaceutical Corporation","enrolled":36,"outcomes":[]},"route":"/trials/nct07136181/","neighbours":{"cancer":[{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}]}}